Solitary fibrous tumor — a fibroblastic mesenchymal neoplasm defined at the molecular level by an inversion within chromosome 12q13, der(12)(q13;q13), generating the NAB2-STAT6 gene fusion that fuses the NAB2 repressor gene to the STAT6 transcriptional coactivator gene, producing a fusion protein whose constitutive transcriptional activation drives CD34-positive fibroblastic proliferation through a STAT6-mediated mechanism — presents across an extraordinarily wide anatomic spectrum, arising in the pleura (where it was historically designated hemangiopericytoma or fibrous mesothelioma before molecular reclassification), the intracranial meninges and dura (where the entity previously called meningeal hemangiopericytoma is now recognized as meningeal SFT, characterized by the same NAB2-STAT6 fusion), the orbit, sinonasal cavity, mediastinum, retroperitoneum, abdominal cavity, pelvis, liver, thyroid, soft tissues of the extremities and trunk, and virtually every other anatomic compartment in which mesenchymal tissue exists, making SFT one of the most anatomically catholic soft tissue neoplasms in oncology and posing diagnostic challenges whose resolution depends entirely on the molecular confirmation of NAB2-STAT6 fusion in a lesion whose morphologic differential diagnosis spans the entire histopathologic landscape of spindle cell neoplasms. Histologically, SFT exhibits a patternless architecture of alternating hypercellular and hypocellular zones traversed by prominent branching hemangiopericytoma-like (staghorn) vessels with hyalinized vessel walls — an architectural signature that in its classic form is sufficiently distinctive to raise the SFT diagnosis — with spindle to oval cells showing bland ovoid nuclei, scant cytoplasm, and absent to low mitotic activity in typical low-grade cases, while malignant SFT (defined by the presence of four or more mitoses per ten high-power fields, hypercellularity, nuclear pleomorphism, tumor necrosis, or dedifferentiation to a high-grade undifferentiated morphology) carries a substantially worse prognosis with a ten-year metastatic rate of 35–50% in contemporary series. The immunophenotypic profile of SFT — characterized by strong and diffuse CD34 positivity, STAT6 nuclear immunoreactivity (a highly sensitive and specific diagnostic marker reflecting the STAT6 fusion protein's nuclear localization), CD99 and bcl-2 expression, and negativity for S100, desmin, and most epithelial markers — provides the immunohistochemical evidence that guides the SFT diagnosis in routine clinical pathology, while confirmatory NAB2-STAT6 fusion detection by RNA sequencing (which identifies the specific NAB2 exon - STAT6 exon fusion type, with prognostic implications: NAB2 exon 4-STAT6 exon 2 fusions being more common in meningeal SFT and associated with younger patients and female predominance, while NAB2 exon 6-STAT6 exon 16/17 fusions predominate in pleural SFT and are associated with higher-grade biology) establishes the molecular diagnosis in diagnostically challenging cases. A defining clinical feature of SFT that sets it apart from most other soft tissue sarcomas and creates specific management challenges is the propensity of a subset of SFTs — particularly large, abdominal, and pelvic tumors — to secrete insulin-like growth factor 2 (IGF-2) in a big IGF-2 form that escapes the normal IGF-binding protein regulatory axis, producing paraneoplastic non-islet cell tumor hypoglycemia (NICTH, also called Doege-Potter syndrome) characterized by severe, life-threatening, fasting hypoglycemia that may occur years before the SFT itself is diagnosed, requiring aggressive glucose supplementation, corticosteroid and glucagon therapy, and ultimately surgical resection or debulking of the IGF-2-producing tumor as the only definitive treatment for the metabolic crisis. The somatostatin receptor expression by SFT — detected by somatostatin receptor scintigraphy (Octreoscan) and particularly by DOTATATE PET/CT with high sensitivity — has created an entirely novel systemic treatment avenue for advanced or metastatic malignant SFT: peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lu-177-DOTATATE, Lutathera), a treatment approved for well-differentiated neuroendocrine tumors with somatostatin receptor expression that has shown meaningful disease control in retrospective and prospective series of malignant SFT patients at centers with PRRT expertise. Sunitinib and other multi-kinase inhibitors have demonstrated meaningful activity in advanced SFT, with objective response rates of 10–20% and disease stabilization rates that have established sunitinib as a treatment option for patients with progressive metastatic SFT who are not PRRT candidates. The multidisciplinary team for SFT — thoracic surgeons managing pleural and mediastinal SFT resection (including extended pleural resections for large pleural-based tumors), neurosurgeons resecting meningeal and intracranial SFT (where the same entity was previously managed under the hemangiopericytoma designation with a different understanding of recurrence risk), abdominal and pelvic surgeons resecting the retroperitoneal, hepatic, and pelvic SFTs that are most commonly associated with Doege-Potter syndrome, nuclear medicine physicians performing DOTATATE PET and administering PRRT, endocrinology consultants managing paraneoplastic hypoglycemia, molecular pathologists confirming NAB2-STAT6 fusion and characterizing fusion type, and medical oncologists managing sunitinib and PRRT eligibility evaluation — constitutes a care ecosystem whose coordination and clinical decision-making depends entirely on the continuous, reliable availability of the digital platforms that orchestrate it.
Solitary fibrous tumor technology platforms — whether supporting the thoracic surgery operative planning workflows for large pleural-based SFT resection (where CT and PET imaging must accurately characterize the tumor's relationship to the pulmonary hilum, diaphragm, and chest wall to plan the extent of pleural dissection), neurosurgical platforms managing intracranial and meningeal SFT resection and post-operative surveillance for a disease whose meningeal recurrence rate after Simpson grade I-IV resection substantially exceeds what was historically reported for meningeal hemangiopericytoma and may require adjuvant radiation therapy to the resection bed, abdominal surgery platforms managing the retroperitoneal and pelvic SFT resections most commonly associated with Doege-Potter syndrome (where pre-operative glucose management with overnight dextrose infusion and intraoperative insulin-like growth factor level monitoring may be required, and where the metabolic crisis of severe hypoglycemia during induction of anesthesia for tumor resection represents a life-threatening perioperative risk), endocrinology and internal medicine platforms managing the paraneoplastic hypoglycemia of Doege-Potter syndrome across the pre-operative, intraoperative, and post-operative periods (where glucose monitoring frequency requirements of every 30–60 minutes during the perioperative period generate continuous data streams requiring platform availability), nuclear medicine platforms managing DOTATATE PET/CT imaging and PRRT administration with Lu-177-DOTATATE (where PRRT therapy cycles require platforms managing pre-PRRT dosimetry assessment, amino acid infusion co-administration records, post-PRRT whole-body scan dosimetry documentation, and hematologic and renal toxicity monitoring across multiple treatment cycles), molecular pathology platforms performing NAB2-STAT6 fusion confirmation by RNA sequencing and STAT6 nuclear IHC, sunitinib targeted therapy management platforms tracking adverse effects and tumor response, and patient portals supporting patients managing SFT across what may be a years-long surveillance and treatment trajectory given the disease's characteristically indolent pace — must maintain the availability and performance standards that SFT's broad anatomic distribution, paraneoplastic metabolic complexity, somatostatin receptor-directed PRRT therapy, molecular diagnostic precision, and prolonged surveillance demands require. This guide explains why SFT tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the anatomically diverse surgical complexity, Doege-Potter syndrome metabolic management, PRRT nuclear medicine demands, and NAB2-STAT6 molecular diagnostic rigor of modern SFT care.
Why Solitary Fibrous Tumor Tech Platforms Require Specialized Monitoring Attention
Solitary fibrous tumor management is defined by anatomically diverse surgical resection across thoracic, neurosurgical, and abdominal operative contexts, paraneoplastic hypoglycemia (Doege-Potter syndrome) management requiring intensive perioperative glucose monitoring, DOTATATE PET-directed PRRT with Lu-177-DOTATATE for somatostatin receptor-positive advanced disease, NAB2-STAT6 molecular diagnostic confirmation by RNA sequencing, sunitinib targeted therapy management, long-term multidisciplinary surveillance for a disease with characteristically late recurrence, and tumor board coordination across thoracic surgery, neurosurgery, abdominal surgery, nuclear medicine, endocrinology, molecular pathology, and medical oncology. Technology failures in any of these areas create clinical disruptions calibrated to the perioperative metabolic complexity, PRRT nuclear medicine demands, and molecular diagnostic weight unique to SFT.
Thoracic surgery platforms manage pleural and mediastinal SFT resection with pulmonary and diaphragmatic involvement. Large pleural-based SFT — where tumors may grow to 20–30 cm within the pleural space before causing compressive symptoms, attached to the visceral or parietal pleura via a pedicle (pedunculated) or sessile implantation, with malignant behavior associated with sessile attachment, pleural invasion, tumor necrosis, and high mitotic rate — requires platforms managing CT thorax imaging access for pleural attachment characterization, PET imaging access for metabolic activity assessment, thoracic surgery operative planning records, video-assisted or open pleural resection documentation, and post-operative pulmonary expansion surveillance imaging access. Monitor thoracic surgery platforms at 1-minute intervals during business hours and operative windows.
Neurosurgical platforms require reliable access for meningeal SFT resection and post-operative surveillance. Intracranial and spinal meningeal SFT — the entity previously classified as meningeal hemangiopericytoma, now recognized to carry a very high recurrence rate (local recurrence in 30–90% of patients across series with long follow-up) and a propensity for delayed extracranial metastasis to bone, liver, and lung years to decades after initial cranial resection (a delayed metastatic pattern that mandates lifelong systemic surveillance beyond the intracranial field) — requires platforms managing MRI brain and spine imaging access, neurosurgical operative records documenting Simpson resection grade, adjuvant radiation therapy records for post-operative cranial radiotherapy or radiosurgery to the resection bed, and post-operative MRI surveillance scheduling for local recurrence detection. Monitor neurosurgical platforms at 1-minute intervals during business hours and active operative windows.
Doege-Potter syndrome management platforms must support intensive perioperative glucose monitoring and endocrine management. Paraneoplastic non-islet cell tumor hypoglycemia from SFT-derived big IGF-2 — where blood glucose levels may drop to 20–40 mg/dL during fasting, requiring continuous glucose infusion, corticosteroid (dexamethasone) therapy to suppress IGF-2 secretion and induce gluconeogenesis, and glucagon for acute rescue — creates an endocrine monitoring platform requirement where perioperative glucose measurements every 30–60 minutes generate a continuous data stream that must be accessible to both the surgical team (who must know the intraoperative glucose trajectory as tumor vascularity is divided and IGF-2 secretion plummets following tumor removal, creating risk of post-operative rebound hyperglycemia as the hypoglycemia-driving IGF-2 source is eliminated) and the endocrinology team managing post-operative glucose normalization. Monitor endocrinology and glucose management platforms at 1-minute intervals during active perioperative windows for Doege-Potter syndrome patients.
DOTATATE PET and PRRT platforms require continuous availability for nuclear medicine imaging and therapy cycles. DOTATATE PET/CT — performed to confirm somatostatin receptor expression before PRRT candidacy determination, and used to assess treatment response after each Lu-177-DOTATATE cycle — requires nuclear medicine imaging platforms that are available during scheduled imaging appointments and that can deliver DOTATATE PET results to the referring oncologist and nuclear medicine physician in a timely manner so PRRT eligibility can be assessed before the treatment window closes. PRRT administration with Lu-177-DOTATATE — administered in four cycles at eight-week intervals, with each cycle requiring amino acid infusion co-administration (nephroprotective lysine-arginine infusion to reduce renal tubular reabsorption of radiolabeled peptide), post-infusion whole-body gamma scintigraphy for dosimetry assessment, and scheduled hematologic and renal function monitoring — requires platforms managing PRRT cycle scheduling, amino acid infusion records, dosimetry scan documentation, and toxicity monitoring. Monitor DOTATATE PET and PRRT management platforms at 1-minute intervals during business hours and active PRRT administration sessions.
NAB2-STAT6 molecular diagnostics platforms direct systemic therapy strategy and PRRT eligibility. RNA sequencing confirmation of NAB2-STAT6 fusion — establishing the SFT diagnosis in a spindle cell neoplasm whose differential diagnosis may include solitary fibrous tumor versus synovial sarcoma, hemangiopericytoma-pattern tumors, sarcomatoid mesothelioma, or desmoid fibromatosis — and STAT6 nuclear IHC screening (a sensitive and specific marker whose diffuse strong nuclear positivity is highly specific for NAB2-STAT6 fusion) together provide the molecular confirmation that directs the SFT diagnosis and enables subsequent DOTATATE PET and PRRT eligibility assessment. Monitor NAB2-STAT6 molecular diagnostics platforms at 1-minute intervals during business hours.
What to Monitor on a Solitary Fibrous Tumor Tech Platform
Thoracic Surgery Planning and Pleural SFT Resection
Monitor CT thorax imaging access for pleural attachment and mediastinal involvement characterization, PET imaging access for metabolic activity assessment and mediastinal nodal involvement evaluation, thoracic surgery operative planning records, video-assisted thoracoscopic or open thoracotomy pleural resection documentation, pulmonary function test records, post-operative chest drain management and pleural re-expansion surveillance imaging access, and adjuvant radiotherapy records for malignant pleural SFT with positive margins at 1-minute intervals during business hours and operative windows. Alert immediately during active thoracic operative sessions.
Neurosurgical Management and Intracranial SFT
Monitor MRI brain and spine imaging access for meningeal SFT extent and dural attachment characterization, neurosurgical operative records documenting Simpson resection grade and extent of dural resection, pre-operative angiography records for highly vascular meningeal SFT requiring pre-operative embolization, adjuvant radiation therapy records for post-operative cranial radiotherapy or stereotactic radiosurgery to the surgical bed, post-operative MRI brain surveillance scheduling for local recurrence detection (at six-monthly intervals for the first three years given the high meningeal recurrence rate), and systemic staging CT and bone scan records for extracranial metastasis surveillance (given meningeal SFT's propensity for delayed skeletal and hepatic metastases years after cranial resection) at 1-minute intervals during business hours and operative windows. Alert immediately during active neurosurgical operative sessions and post-operative MRI review periods.
Doege-Potter Syndrome and Paraneoplastic Hypoglycemia Management
Monitor endocrinology consultation documentation for patients presenting with severe fasting hypoglycemia and retroperitoneal or pelvic mass, IGF-2 and big IGF-2 serum assay results and trend access, continuous glucose monitoring records and blood glucose log access (where intraoperative and perioperative glucose measurements every 30–60 minutes generate high-frequency data), dexamethasone dosing records for IGF-2 suppression and gluconeogenesis induction, glucose infusion rate management records during pre-operative preparation and intraoperative tumor resection, glucagon rescue administration documentation, post-operative glucose normalization tracking (where removal of the IGF-2-producing tumor requires dexamethasone tapering and glucose infusion weaning as endogenous glucose regulation is restored), and outpatient continuous glucose monitoring records for patients with unresectable SFT managing chronic paraneoplastic hypoglycemia at 1-minute intervals during active perioperative windows and during active outpatient hypoglycemia management cycles. Alert immediately during perioperative sessions for Doege-Potter syndrome patients — intraoperative hypoglycemia not detected because a glucose monitoring platform is unavailable during the operative session creates a life-threatening anesthetic risk.
DOTATATE PET Imaging and Nuclear Medicine
Monitor DOTATATE PET/CT imaging scheduling and result routing, somatostatin receptor quantification and Krenning score documentation, PET imaging comparison records across pre-PRRT and post-cycle assessments, nuclear medicine consultation documentation for PRRT eligibility assessment, DOTATATE PET result access for multidisciplinary tumor board review of PRRT candidacy, and scintigraphy result access for SFT anatomic mapping across primary and metastatic sites at 1-minute intervals during business hours and active nuclear medicine imaging sessions. Alert immediately during scheduled DOTATATE PET reporting windows when results are required for imminent tumor board PRRT eligibility discussions.
PRRT Administration and Monitoring
Monitor Lu-177-DOTATATE PRRT cycle scheduling and administration records, amino acid infusion (lysine-arginine nephroprotection) co-administration documentation, post-PRRT whole-body gamma scintigraphy dosimetry scan records, renal dosimetry calculation and cumulative renal dose monitoring records, hematologic toxicity monitoring (complete blood count at defined intervals after each PRRT cycle, given the myelosuppressive potential of beta-emitting lutetium-177 to circulating marrow precursors), renal function monitoring records (creatinine and GFR tracking across PRRT cycles, given radiolabeled peptide renal tubular uptake creating risk of nephrotoxicity that cumulative renal dose monitoring aims to prevent), and RECIST and DOTATATE PET-based tumor response assessment records across the four-cycle PRRT course at 1-minute intervals during business hours and active PRRT administration sessions. Alert immediately during active PRRT infusion sessions — amino acid infusion and Lu-177-DOTATATE co-administration require simultaneous platform access for administration documentation, and post-infusion dosimetry scan scheduling must proceed without delay.
NAB2-STAT6 Molecular Diagnostics
Monitor RNA sequencing panel ordering and result routing for NAB2-STAT6 fusion confirmation, STAT6 nuclear immunohistochemistry staining and result access, NAB2-STAT6 fusion type characterization records (NAB2 exon - STAT6 exon junction identification, which carries prognostic information), molecular pathology consultation documentation, differential diagnosis records distinguishing SFT from synovial sarcoma, desmoid fibromatosis, sarcomatoid mesothelioma, and other CD34-positive spindle cell tumors, and clinical trial eligibility determination records dependent on molecular confirmation at 1-minute intervals during business hours. Alert immediately — NAB2-STAT6 molecular diagnostics platform failures delay the SFT diagnostic confirmation that enables DOTATATE PET ordering, PRRT eligibility assessment, and histotype-specific sunitinib treatment initiation.
Sunitinib Targeted Therapy Management
Monitor sunitinib oral therapy prescribing and refill records, blood pressure surveillance logs and antihypertensive dose adjustment documentation, hand-foot skin reaction grading records and dose modification history, TSH and thyroid function monitoring, hepatic transaminase surveillance, RECIST CT restaging scheduling and tumor response records, dose modification history, and clinical trial protocol compliance for investigational sunitinib regimens at 1-minute intervals during business hours. Alert immediately during active sunitinib treatment cycles when toxicity grading and dose modification decisions require platform access.
Abdominal and Pelvic SFT Surgical Management
Monitor CT and MRI imaging access for retroperitoneal, hepatic, and pelvic SFT characterization, abdominal surgery operative planning records, hepatic resection records for liver-based SFT, pelvic SFT resection documentation with urology and gynecologic oncology coordination records when bladder or gynecologic structures are involved, post-operative complication surveillance, and Doege-Potter syndrome management documentation for the abdominal and pelvic SFTs most commonly associated with big IGF-2 secretion at 1-minute intervals during business hours and active operative windows. Alert immediately during operative sessions for abdominal SFT with Doege-Potter syndrome.
Long-Term Surveillance and Recurrence Monitoring
Monitor long-term CT thorax/abdomen/pelvis surveillance scheduling for systemic recurrence monitoring (particularly for meningeal SFT with delayed extracranial metastatic potential), bone scan scheduling and result access for skeletal metastasis surveillance in meningeal SFT patients, hepatic imaging surveillance records, DOTATATE PET restaging access for PRRT-treated patients, multidisciplinary recurrence management discussion records, and re-resection or PRRT re-treatment eligibility assessment documentation at 1-minute intervals during business hours. Alert during scheduled surveillance imaging reporting windows.
Multidisciplinary Tumor Board Coordination
Monitor MDT case presentation record access and imaging and pathology report synchronization across thoracic surgery, neurosurgery, abdominal surgery, nuclear medicine, endocrinology, molecular pathology, and medical oncology disciplines, PRRT eligibility assessment discussion records, sunitinib initiation decision documentation, clinical trial enrollment discussion and eligibility records, and Doege-Potter syndrome management strategy consensus documentation at 1-minute intervals during business hours. Alert immediately during scheduled tumor board sessions.
Patient Communication Portal
Monitor patient portal availability for symptom reporting during active sunitinib or PRRT treatment cycles, glucose monitoring log submission for Doege-Potter syndrome patients managing chronic paraneoplastic hypoglycemia, appointment scheduling and surveillance imaging scheduling access, medication management and refill request access, and educational resource access supporting patients navigating a characteristically long SFT disease course with periodic recurrence. Alert on sustained failures during business and evening hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. SFT programs coordinate across thoracic surgery, neurosurgery, abdominal surgery, nuclear medicine, endocrinology, molecular pathology, and medical oncology — authentication failures simultaneously block every member of a multidisciplinary care team managing patients on PRRT cycles, active sunitinib regimens, and Doege-Potter syndrome glucose management programs where platform access during metabolic emergencies is critical.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all patient portals, surgical planning systems, nuclear medicine imaging and PRRT management interfaces, molecular diagnostics platforms, targeted therapy management systems, and tumor board coordination tools with 30-day advance alerting.
HIPAA and Oncology Data Privacy Considerations
Solitary fibrous tumor technology platforms handle sensitive PHI including NAB2-STAT6 molecular diagnostic records (with RNA sequencing data that captures the tumor's fusion transcript and may be accompanied by germline variant calls in comprehensive sequencing panels), DOTATATE PET imaging records documenting whole-body somatostatin receptor distribution across primary and metastatic SFT sites, Lu-177-DOTATATE PRRT administration records including radiation dosimetry data, Doege-Potter syndrome management records documenting severe paraneoplastic hypoglycemia with blood glucose logs capturing daily metabolic vulnerability in patients managing chronic paraneoplastic endocrine crisis, neurosurgical operative records from intracranial meningeal SFT resection including detailed neuroanatomic documentation, and long-term recurrence surveillance imaging records for patients monitored across decades given meningeal SFT's pattern of delayed extracranial metastasis. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components.
For platforms managing PRRT administration records — where radiation therapy dosimetry documentation for nuclear medicine treatment creates specialized data types at the intersection of oncology PHI and radiation safety records — data access control standards must reflect both HIPAA PHI protection requirements and institutional radiation safety record governance. For platforms managing Doege-Potter syndrome glucose monitoring logs, the longitudinal metabolic vulnerability data captured requires sensitivity protections appropriate to chronic endocrine disease management records. Uptime monitoring provides the operational documentation of PHI system availability that supports HIPAA Security Rule administrative safeguard compliance for SFT programs managing oncology PHI across anatomically diverse surgical, nuclear medicine, endocrine, and systemic therapy care settings.
Alerting Strategy for Solitary Fibrous Tumor Tech Platforms
Immediate alerting 24/7: Authentication and core platform access. SFT patients with active Doege-Potter syndrome may require urgent clinical team access for severe hypoglycemia management at any hour; patients on PRRT cycles and sunitinib may develop toxicities requiring urgent care team access outside business hours.
Immediate alerting during operative and treatment sessions: Thoracic surgery platforms during active pleural SFT resection; neurosurgical platforms during intracranial meningeal SFT craniotomy; abdominal surgery platforms during retroperitoneal SFT resection with Doege-Potter syndrome perioperative glucose management; PRRT administration platforms during active Lu-177-DOTATATE infusion sessions. These platforms cannot fail without immediate clinical intervention.
Immediate business-hours alert: Doege-Potter syndrome glucose management platforms during active endocrine monitoring cycles (hypoglycemia crises cannot tolerate delayed detection), NAB2-STAT6 molecular diagnostics platforms during active reporting periods, DOTATATE PET result routing during scheduled imaging report periods, sunitinib toxicity management platforms during active treatment cycles, and multidisciplinary tumor board coordination platforms during scheduled MDT sessions.
Sustained-failure alert (10–15 minutes): Patient communication portal, long-term surveillance imaging scheduling platforms, and post-treatment recurrence monitoring systems.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms SFT platform availability from the geographies where specialist centers — nuclear medicine programs with Lu-177-DOTATATE PRRT capability, high-volume neurosurgical programs managing meningeal SFT, and abdominal surgery programs experienced in Doege-Potter syndrome perioperative management — access the system, important given SFT's rarity and the geographic concentration of PRRT and meningeal SFT expertise.
Status Page for Solitary Fibrous Tumor Care Team Communication
A real-time status page gives thoracic surgeons planning pleural SFT resection, neurosurgeons managing intracranial meningeal SFT craniotomy and post-operative surveillance, abdominal surgeons coordinating retroperitoneal SFT resection with Doege-Potter syndrome metabolic management, nuclear medicine physicians performing DOTATATE PET and administering PRRT, endocrinologists managing paraneoplastic hypoglycemia, molecular pathologists routing NAB2-STAT6 RNA sequencing results, medical oncologists managing sunitinib and PRRT eligibility evaluation, and tumor board coordinators immediate platform visibility without requiring inbound IT support contact. During a PRRT administration platform outage occurring during an active Lu-177-DOTATATE infusion session for an SFT patient on their third treatment cycle — where the nuclear medicine physician administering the radiolabeled peptide requires simultaneous access to the amino acid infusion rate records, the prior cycle dosimetry calculations showing cumulative renal dose approaching the safety threshold, and the post-cycle hematologic monitoring schedule to determine whether the planned cycle can proceed as scheduled or requires dose reduction given renal function trends — a status page enables the nuclear medicine and oncology team to immediately activate documented PRRT downtime procedures, access emergency dosimetry records through backup pathways, and communicate the platform status to the administering team before the treatment cycle is compromised.
Include the status page URL in PRRT administration downtime procedures, Doege-Potter syndrome perioperative glucose management fallback protocols, NAB2-STAT6 diagnostic emergency access workflows, and neurosurgical meningeal SFT operative fallback protocols.
Vigilmon Setup for Solitary Fibrous Tumor Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Thoracic surgery planning (pleural SFT) | 1 min | Slack + PagerDuty (surgical hours) | | Neurosurgical management (meningeal SFT) | 1 min | Slack + PagerDuty (surgical hours) | | Doege-Potter syndrome / glucose management | 1 min | Slack + PagerDuty (perioperative hours) | | DOTATATE PET imaging and nuclear medicine | 1 min | Slack + PagerDuty (business hours) | | PRRT administration and monitoring | 1 min | Slack + PagerDuty (treatment hours) | | NAB2-STAT6 molecular diagnostics | 1 min | Slack + PagerDuty (business hours) | | Sunitinib targeted therapy management | 1 min | Slack + PagerDuty (business hours) | | Long-term surveillance and recurrence monitoring | 2 min | Slack (business hours) | | Multidisciplinary tumor board coordination | 1 min | Slack + PagerDuty (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure thoracic surgery planning with immediate alerting during pleural SFT resection operative windows
- Add neurosurgical management with immediate alerting during intracranial meningeal SFT craniotomy and post-operative MRI surveillance reporting windows
- Configure Doege-Potter syndrome glucose management with immediate alerting during perioperative sessions for patients with paraneoplastic hypoglycemia
- Add DOTATATE PET imaging with immediate alerting during scheduled imaging result reporting windows ahead of PRRT eligibility assessments
- Configure PRRT administration with immediate alerting during active Lu-177-DOTATATE infusion sessions and post-cycle dosimetry scanning
- Add NAB2-STAT6 RNA sequencing and STAT6 IHC molecular diagnostics platforms with immediate business-hours alerting
- Configure sunitinib targeted therapy management with immediate business-hours alerting during active treatment cycles
- Add abdominal and pelvic SFT surgical platforms with immediate alerting during operative windows for Doege-Potter syndrome patients
- Configure long-term surveillance scheduling with sustained-failure alerting
- Add multidisciplinary tumor board coordination with immediate alerting during scheduled MDT sessions
- Configure patient communication portal monitoring for glucose log submission, symptom reporting, and surveillance scheduling access
- Enable SSL certificate monitoring across all clinical, patient-facing, nuclear medicine, molecular diagnostics, and targeted therapy management domains
- Add the status page URL to PRRT administration downtime procedures, Doege-Potter syndrome perioperative fallback protocols, NAB2-STAT6 diagnostic emergency workflows, and neurosurgical SFT operative fallback procedures
Conclusion
Solitary fibrous tumor technology platforms are embedded in clinical decisions where PRRT administration platform availability during an active Lu-177-DOTATATE infusion session for an SFT patient on their second PRRT cycle — where the nuclear medicine physician must simultaneously access the cumulative renal dosimetry from cycle one, the current renal function trend showing GFR decline from 82 to 68 mL/min since the previous cycle, and the amino acid infusion rate protocol adjusted for the patient's body weight to determine whether the nephroprotective infusion rate must be increased to compensate for the observed renal function reduction before the radiolabeled peptide is administered — cannot fail without creating a treatment safety gap in a therapy where cumulative renal radiation dose management is the primary determinant of long-term nephrotoxicity risk, and where the nuclear medicine team's ability to access real-time dosimetry history during the active treatment session is not a convenience feature but a patient safety requirement; where Doege-Potter syndrome glucose management platform availability during the intraoperative period of a retroperitoneal SFT resection for a patient whose pre-operative blood glucose on dexamethasone and continuous dextrose infusion was 58 mg/dL one hour before induction — where intraoperative glucose measurements must be accessible to both the anesthesiologist managing the infusion rate and the endocrinologist on call, who must know the glucose trajectory at the moment the tumor's vascular pedicle is divided and the IGF-2 source is eliminated, because the transition from IGF-2-driven hypoglycemia to the post-resection period of glucose normalization may require rapid adjustment of the glucose infusion rate to prevent the equally dangerous rebound hyperglycemia that follows tumor removal — determines whether a life-threatening metabolic transition is managed with real-time data or managed blindly; and where NAB2-STAT6 molecular diagnostics platform availability during RNA sequencing result routing for a patient with a large retroperitoneal spindle cell tumor whose differential diagnosis includes SFT versus synovial sarcoma versus desmoid fibromatosis determines whether the nuclear medicine physician can immediately order a DOTATATE PET to confirm somatostatin receptor expression and proceed with PRRT eligibility assessment, or must wait until the molecular result is manually retrieved and re-entered into the imaging ordering system — a delay whose consequence is measured not merely in days but in the displacement of the PRRT cycle timing relative to the treatment window that provides the best disease control opportunity for a patient whose tumor has already begun progressing on sunitinib. These are not IT incidents. They are clinical disruptions in the management of a rare soft tissue neoplasm defined by its anatomic diversity, paraneoplastic metabolic complexity, somatostatin receptor-directed nuclear medicine therapy, and prolonged surveillance demands, where platform availability shapes PRRT dosimetry safety, perioperative glucose management, and molecular diagnostic access that collectively determine whether SFT patients receive the PRRT therapy, Doege-Potter syndrome management, and molecular confirmation that constitute the standard of excellence in modern SFT care.
Uptime monitoring gives SFT tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to nuclear medicine programs, thoracic and neurosurgical teams, endocrinology departments, and compliance auditors that the platform's operational reliability matches the PRRT complexity, paraneoplastic metabolic management demands, molecular diagnostic rigor, and long-term surveillance management of modern SFT care.
Start monitoring your solitary fibrous tumor tech platform for free at vigilmon.online
Tags: #monitoring #solitaryfibroustumor #SFT #NAB2STAT6 #hemangiopericytoma #meningealSFT #DoegePortersyndrome #paraneoplastichypoglycemia #PRRT #DOTATATE #lutetium177 #somatostatinreceptor #sunitinib #softtissuesarcoma #raretumor #nuclearmedicine #neurosurgery #thoracicsurgery #moleculardiagnostics #multidisciplinaryoncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre